Trial Profile

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etakafusp alfa (Primary) ; Rilvegostomig (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ALTAIR
Sponsors AstraZeneca

Most Recent Events

30 May 2025 Status changed from planning to not yet recruiting.
15 Jan 2025 New trial record
07 Jan 2025 Asher Bio announced an agreement with AstraZeneca to supply etakafusp alfa (formerly known as AB248), to be evaluated in combination with rilvegostomig, in patients with advanced or metastatic NSCLC.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com